ABIVAX Société Anonyme reports Q3 results
Source: SeekingAlpha
2025-12-15 16:21:50 ET
More on Abivax
- Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026
- Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026
- Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster
- Eli Lilly acquisition rumors reportedly fuel Abivax rally
- Abivax gains amid takeover speculation
Read the full article on Seeking Alpha
For further details see:
ABIVAX Société Anonyme reports Q3 results
Abivax
NASDAQ: AAVXF
AAVXF Trading
0.8% G/L:
$125.656 Last:
700 Volume:
$124.66 Open:
